MEDIA ARE REQUESTED TO RSVP WITH THEIR NAME AND MEDIA ORGANIZATION TO SUE_WALITSKY@CARDIN.SENATE.GOV
For Immediate Release
CONTACT: Sue Walitsky 202-224-4524 or 202-320-0819 (cell)
October 25, 2013
*** MEDIA ADVISORY ***
CARDIN TO VISIT BETHESDA-BASED BRAINSCOPE TO
HIGHLIGHT MARYLAND INNOVATIONS IN MEDICAL
“Early assessment of traumatic brain injuries and concussions could save
lives on battle fields and playing fields”
TODAY/Friday, October 25 at 1:30PM, U.S. Senator Ben Cardin (D-MD), will visit BrainScope Company, Inc. of Bethesda to meet with employees and learn how their mission to redefine how traumatic brain injuries and concussions are assessed, for soldiers and athletes alike, is creating jobs for Marylanders. This is the latest stop on Senator Cardin’s “Made in Maryland” jobs tour. Throughout this year, he has been touring manufacturers and innovators throughout Maryland to highlight the diverse products being created and produced here and adding to the growth of our economy
“The federal government should be a partner, not an obstacle, helping to assist small businesses and other companies as they strive to be the best and most innovative in their field,” Senator Cardin said. “Giant leaps in medical technology are being made right here in Maryland. BrainScope’s technology has the potential to save lives and support high quality, high-paying jobs in our community.”
WHAT: Senator Cardin Visit to BrainScope Company, Inc.
WHEN: Friday, Oct. 25 – 1:30 PM
WHERE: 4350 East-West Highway, Suite 1050 (10th Floor)
Bethesda, MD 20814
BrainScope® Company, Inc. is a privately held neurotechnology company focused on the development of medical devices to aid in the assessment of traumatic brain injury (TBI), and its milder presentation, commonly referred to as "concussion". According to the International Brain Injury Association, TBI is a leading cause of death and disability worldwide. Continued headlines on soldiers returning from overseas with TBIs and the serious dangers of sports concussions have elevated awareness of this important global public health issue. Based on seven years of clinical studies and product development in the field of TBI, BrainScope’s Ahead® system addresses the significant clinical need for rapid, objective identification of patients most likely to have sustained a TBI, particularly for those patients who do not present as seriously impaired. The company has been awarded research and development contracts valued in excess of $10 million by the U.S. Department of Defense, and has also received funding from The Maryland Department of Business and Economic Development (DBED) through its Maryland Venture Fund program. BrainScope devices under development are for investigational use only and have not been submitted to FDA for premarket review.